Biohaven Licenses Epilepsy Drug for $795M
Biohaven signed an agreement with SK Biopharmaceuticals to license its epilepsy drug platform and Opakalim. The deal is valued at up to 795 million dollars, according to a joint company statement.
BIOHAVEN LTD licensed its epilepsy drug platform, including Opakalim, to SK BIOPHARMACEUTICALS CO LTD for up to $795 million. The deal expands the drug's reach into South Korea and global markets. The agreement provides Biohaven with substantial upfront capital to advance its broader neuroscience pipeline.
### Deal Terms and Milestones The agreement includes an upfront payment alongside tiered royalties and development milestones. SK Biopharmaceuticals will handle regional commercialization and clinical development for the platform. The collaboration aims to accelerate market entry for next-generation neurological treatments.
